Health Care & Life Sciences » Pharmaceuticals | Astellas Pharma Inc.

Astellas Pharma Inc. | Mutual Funds

Mutual Funds that own Astellas Pharma Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Nomura Asset NIKKEI 225 Index ETF (1321)
47,220,000
2.38%
640,000
1.54%
07/31/2018
Nomura Asset TOPIX ETF Fund (1306)
31,058,500
1.57%
491,700
0.73%
07/31/2018
Government Pension Fund - Global (The)
28,224,332
1.43%
424,881
0.06%
12/31/2017
Vanguard Total International Stock Index Fund
28,048,028
1.42%
349,700
0.14%
07/31/2018
Vanguard Health Care Fund
26,798,900
1.35%
-5,402,500
0.9%
06/30/2018
Nikko Asset Listed Index 225 ETF (1330)
23,950,000
1.21%
10,000
1.52%
08/20/2018
Daiwa Asset NIKKEI 225 ETF (1320)
21,140,000
1.07%
-80,000
1.52%
07/31/2018
Stichting Pensioenfonds ABP (Global Equity Portfolio)
17,423,059
0.88%
2,642,190
0.06%
03/31/2018
IVA Worldwide Fund
15,312,400
0.77%
-6,495,900
3.18%
03/31/2018
Daiwa Asset TOPIX Listed ETF (1305)
15,244,500
0.77%
348,500
0.75%
07/31/2018

About Astellas Pharma

View Profile
Address
2-5-1 Nihonbashi-Honcho
Tokyo Tokyo 103
Japan
Employees -
Website http://www.astellas.com
Updated 07/08/2019
Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.